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Figure S8. Relationship between total IgG ELISA titers and % GIA. (A) Spearman’s correlation of 
serum IgG ELISA titers against AMA1 for the 3D7 versus FVO alleles at day 84, n = 8. (B) Relationship 
between 3D7 strain % GIA and FVO strain % GIA using purified IgG at 10mg/mL.  
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